Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Atacand For Congestive Heart Failure To Receive FDA Cmte. Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s cardio-renal committee will consider three sub-indications for Atacand in the treatment of congestive heart failure. The meeting will be held on Feb. 24.

You may also be interested in...



Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors

The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure

Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors

The focus of FDA's Cardiovascular & Renal Drugs Advisory Committee review of AstraZeneca's Atacand Feb. 24 will be narrowed to a discussion of concomitant use with angiotensin-converting enzyme inhibitors in treating congestive heart failure

AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit

Combination use with ACE inhibitors will likely be an issue for the Atacand sNDA; the efficacy seen in AstraZeneca’s CHARM studies conflicts with the Val-HeFT data for Novatis’ angiotensin-II receptor blocker Diovan, which showed no added benefit.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel